Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated:  5/30/2012
The Ohio State University AIDS CRS (2301)
mi
from
Colombus, OH
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated: 5/30/2012
The Ohio State University AIDS CRS (2301)
mi
from
Colombus, OH
Click here to add this to my saved trials
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated:  5/30/2012
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated: 5/30/2012
Hosp. of the Univ. of Pennsylvania CRS (6201)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated:  5/30/2012
The Miriam Hospital ACTG CRS (2951)
mi
from
Providence, RI
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated: 5/30/2012
The Miriam Hospital ACTG CRS (2951)
mi
from
Providence, RI
Click here to add this to my saved trials
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated:  5/30/2012
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated: 5/30/2012
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Click here to add this to my saved trials
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated:  5/30/2012
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated: 5/30/2012
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Click here to add this to my saved trials
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated:  5/30/2012
Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
mi
from
Richmond, VA
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated: 5/30/2012
Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
mi
from
Richmond, VA
Click here to add this to my saved trials
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated:  5/30/2012
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Status: Enrolling
Updated: 5/30/2012
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Click here to add this to my saved trials
An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons
An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons
Status: Enrolling
Updated:  6/12/2012
University of Washington Virology Research Clinic
mi
from
Seattle, WA
An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons
An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons
Status: Enrolling
Updated: 6/12/2012
University of Washington Virology Research Clinic
mi
from
Seattle, WA
Click here to add this to my saved trials
Effect of Rosuvastatin on Endothelial Function
Pilot Study of the Effect of Low-Dose Rosuvastatin on Endothelial Function, Oxidative Stress and Inflammatory Parameters in HIV-Infected Individuals With Low HDL Cholesterol Levels and Low to Normal LDL Cholesterol Levels
Status: Enrolling
Updated:  6/14/2012
Hawaii Center for AIDS
mi
from
Honolulu, HI
Effect of Rosuvastatin on Endothelial Function
Pilot Study of the Effect of Low-Dose Rosuvastatin on Endothelial Function, Oxidative Stress and Inflammatory Parameters in HIV-Infected Individuals With Low HDL Cholesterol Levels and Low to Normal LDL Cholesterol Levels
Status: Enrolling
Updated: 6/14/2012
Hawaii Center for AIDS
mi
from
Honolulu, HI
Click here to add this to my saved trials
Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
Antiretroviral Drug Concentrations and HIV Viral Load in Breast Milk and Plasma in HIV+ Women Receiving HAART Therapy: Etravirine PK in Breast Milk and Plasma
Status: Enrolling
Updated:  6/20/2012
LAC+USC MCA Clinic
mi
from
Los Angeles, CA
Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
Antiretroviral Drug Concentrations and HIV Viral Load in Breast Milk and Plasma in HIV+ Women Receiving HAART Therapy: Etravirine PK in Breast Milk and Plasma
Status: Enrolling
Updated: 6/20/2012
LAC+USC MCA Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
HIV Prevention Program for African American Teen Males
A Brief, Clinic-Based, HIV Prevention Program for African American Teen Males
Status: Enrolling
Updated:  6/24/2012
Adolescent Medicine Program, LSU School of Medicine
mi
from
New Orleans, LA
HIV Prevention Program for African American Teen Males
A Brief, Clinic-Based, HIV Prevention Program for African American Teen Males
Status: Enrolling
Updated: 6/24/2012
Adolescent Medicine Program, LSU School of Medicine
mi
from
New Orleans, LA
Click here to add this to my saved trials
Evaluation of Efficacy and Tolerability of Hizentra®
Evaluation of Efficacy and Tolerability of Hizentra® in Subjects Transitioning From Vivaglobin® (16% SCIG Product) to Hizentra® (20% SCIG Product)
Status: Enrolling
Updated:  7/16/2012
University of South Florida
mi
from
St. Petersburg, FL
Evaluation of Efficacy and Tolerability of Hizentra®
Evaluation of Efficacy and Tolerability of Hizentra® in Subjects Transitioning From Vivaglobin® (16% SCIG Product) to Hizentra® (20% SCIG Product)
Status: Enrolling
Updated: 7/16/2012
University of South Florida
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)
To Evaluate Bacteriophage OX174 Antigen as a Useful Immunogen in Patients With Immune Deficiency
Status: Enrolling
Updated:  7/16/2012
University of South Florida
mi
from
St. Petersburg, FL
Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)
To Evaluate Bacteriophage OX174 Antigen as a Useful Immunogen in Patients With Immune Deficiency
Status: Enrolling
Updated: 7/16/2012
University of South Florida
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
A Couple-Based Relationship Strengthening HIV Intervention for Young Parents
Pilot Phase of Couples-Based Intervention to Reduce HIV/STD Risk (Concurrency, Number of Partners, Unprotected Sex), Strengthen Relationships, and Improve Parenting Among Young Parenting Heterosexual Couples
Status: Enrolling
Updated:  7/16/2012
Children's Community Programs of Connecticut
mi
from
New Haven, CT
A Couple-Based Relationship Strengthening HIV Intervention for Young Parents
Pilot Phase of Couples-Based Intervention to Reduce HIV/STD Risk (Concurrency, Number of Partners, Unprotected Sex), Strengthen Relationships, and Improve Parenting Among Young Parenting Heterosexual Couples
Status: Enrolling
Updated: 7/16/2012
Children's Community Programs of Connecticut
mi
from
New Haven, CT
Click here to add this to my saved trials
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Status: Enrolling
Updated:  7/18/2012
Hartford Dispensary
mi
from
Hartford, CT
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Status: Enrolling
Updated: 7/18/2012
Hartford Dispensary
mi
from
Hartford, CT
Click here to add this to my saved trials
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  8/5/2012
Duke University Medical Center Pediatric Blood and Marrow Transplant Program
mi
from
Durham, NC
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 8/5/2012
Duke University Medical Center Pediatric Blood and Marrow Transplant Program
mi
from
Durham, NC
Click here to add this to my saved trials
Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
Integrating Prenatal Care to Reduce HIV/STDs Among Teens: A Translational Study
Status: Enrolling
Updated:  8/12/2012
Centering Pregnancy and Parenting Association
mi
from
Cheshire, CT
Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
Integrating Prenatal Care to Reduce HIV/STDs Among Teens: A Translational Study
Status: Enrolling
Updated: 8/12/2012
Centering Pregnancy and Parenting Association
mi
from
Cheshire, CT
Click here to add this to my saved trials
Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
Integrating Prenatal Care to Reduce HIV/STDs Among Teens: A Translational Study
Status: Enrolling
Updated:  8/12/2012
Yale University Connecticut Women's Health Project
mi
from
New Haven, CT
Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
Integrating Prenatal Care to Reduce HIV/STDs Among Teens: A Translational Study
Status: Enrolling
Updated: 8/12/2012
Yale University Connecticut Women's Health Project
mi
from
New Haven, CT
Click here to add this to my saved trials
Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
Integrating Prenatal Care to Reduce HIV/STDs Among Teens: A Translational Study
Status: Enrolling
Updated:  8/12/2012
Clinical Directors Network
mi
from
New York, NY
Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
Integrating Prenatal Care to Reduce HIV/STDs Among Teens: A Translational Study
Status: Enrolling
Updated: 8/12/2012
Clinical Directors Network
mi
from
New York, NY
Click here to add this to my saved trials
Problems With Immune Recovery in the Gut Tissue
A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution (C)
Status: Enrolling
Updated:  8/30/2012
Univ of Minnesota
mi
from
Minneapolis, MN
Problems With Immune Recovery in the Gut Tissue
A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution (C)
Status: Enrolling
Updated: 8/30/2012
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
A Study to Evaluate the Effect of Metal Cation-Containing Antacids on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Baltimore, MD
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
A Study to Evaluate the Effect of Metal Cation-Containing Antacids on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
A Study to Evaluate the Effect of Metal Cation-Containing Antacids on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen
Status: Enrolling
Updated:  9/7/2012
Clinical Research Facility
mi
from
Baltimore, MD
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
A Study to Evaluate the Effect of Metal Cation-Containing Antacids on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen
Status: Enrolling
Updated: 9/7/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
Southwest Center for HIV/AIDS
mi
from
Phoenix, AZ
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
Southwest Center for HIV/AIDS
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
Health for Life Clinic, PLLC
mi
from
Little Rock, AR
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
Health for Life Clinic, PLLC
mi
from
Little Rock, AR
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
UC Davis Medical Center
mi
from
Sacramento, CA
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
Metropolis Medical Pc
mi
from
San Francisco, CA
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
Metropolis Medical Pc
mi
from
San Francisco, CA
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
Indiana University Hospital
mi
from
Indianapolis, IN
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
Indiana University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
Be Well Medical Center
mi
from
Berkley, MI
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
Be Well Medical Center
mi
from
Berkley, MI
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
Southampton Health Center
mi
from
St Louis, MO
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
Southampton Health Center
mi
from
St Louis, MO
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
I.D. Care Associates
mi
from
Hillsborourgh, NJ
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
I.D. Care Associates
mi
from
Hillsborourgh, NJ
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
Saint Michael's Medical Center
mi
from
Newark, NJ
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
Saint Michael's Medical Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
Infectious Disease Clinic & AI
mi
from
Bronx, NY
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
Infectious Disease Clinic & AI
mi
from
Bronx, NY
Click here to add this to my saved trials
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated:  9/7/2012
James J. Peters VAMC
mi
from
Bronx, NY
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone
Status: Enrolling
Updated: 9/7/2012
James J. Peters VAMC
mi
from
Bronx, NY
Click here to add this to my saved trials
Post-Exposure Prophylaxis in Health Care Workers
A Prospective, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Raltegravir + Truvada Versus Kaletra + Truvada, for Post-exposure Prophylaxis in Health Care Workers
Status: Enrolling
Updated:  9/11/2012
Henry Ford Hospital
mi
from
Detroit, MI
Post-Exposure Prophylaxis in Health Care Workers
A Prospective, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Raltegravir + Truvada Versus Kaletra + Truvada, for Post-exposure Prophylaxis in Health Care Workers
Status: Enrolling
Updated: 9/11/2012
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies
HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies
Status: Enrolling
Updated:  9/12/2012
San Francisco General Hospital
mi
from
San Francisco, CA
HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies
HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies
Status: Enrolling
Updated: 9/12/2012
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load
Status: Enrolling
Updated:  9/18/2012
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load
Status: Enrolling
Updated: 9/18/2012
Ucsf Aids Crs (801)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load
Status: Enrolling
Updated:  9/18/2012
The Ponce de Leon Ctr. CRS (5802)
mi
from
Atlanta, GA
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load
Status: Enrolling
Updated: 9/18/2012
The Ponce de Leon Ctr. CRS (5802)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load
Status: Enrolling
Updated:  9/18/2012
NY Univ. HIV/AIDS CRS (401)
mi
from
New York, NY
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load
Status: Enrolling
Updated: 9/18/2012
NY Univ. HIV/AIDS CRS (401)
mi
from
New York, NY
Click here to add this to my saved trials
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load
Status: Enrolling
Updated:  9/18/2012
Unc Aids Crs
mi
from
Chapel Hill, NC
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load
Status: Enrolling
Updated: 9/18/2012
Unc Aids Crs
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load
Status: Enrolling
Updated:  9/18/2012
Case CRS (2501)
mi
from
Cleveland, OH
Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load
Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load
Status: Enrolling
Updated: 9/18/2012
Case CRS (2501)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Status: Enrolling
Updated:  9/27/2012
Indiana University School of Medicine
mi
from
Indianapolis, IN
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Status: Enrolling
Updated: 9/27/2012
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Status: Enrolling
Updated:  9/27/2012
University of Kentucky Medical Center
mi
from
Lexington, KY
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Status: Enrolling
Updated: 9/27/2012
University of Kentucky Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Status: Enrolling
Updated:  9/27/2012
Washington University School of Medicine
mi
from
St.Louis, MO
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Status: Enrolling
Updated: 9/27/2012
Washington University School of Medicine
mi
from
St.Louis, MO
Click here to add this to my saved trials
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Status: Enrolling
Updated:  9/27/2012
Univ of Pennsylvania
mi
from
Philadelphia, PA
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Status: Enrolling
Updated: 9/27/2012
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Status: Enrolling
Updated:  9/27/2012
Vanderbilt AIDS Clinical Trials Center
mi
from
Nashville, TN
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination
Status: Enrolling
Updated: 9/27/2012
Vanderbilt AIDS Clinical Trials Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Botswana TDF/FTC Oral HIV Prophylaxis Trial
Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana
Status: Enrolling
Updated:  10/1/2012
Centers for Disease Control and Prevention
mi
from
Atlanta, GA
Botswana TDF/FTC Oral HIV Prophylaxis Trial
Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana
Status: Enrolling
Updated: 10/1/2012
Centers for Disease Control and Prevention
mi
from
Atlanta, GA
Click here to add this to my saved trials
Botswana TDF/FTC Oral HIV Prophylaxis Trial
Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana
Status: Enrolling
Updated:  10/1/2012
BOTUSA HIV Prevention Research Unit
mi
from
Francistown and Gaborone,
Botswana TDF/FTC Oral HIV Prophylaxis Trial
Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana
Status: Enrolling
Updated: 10/1/2012
BOTUSA HIV Prevention Research Unit
mi
from
Francistown and Gaborone,
Click here to add this to my saved trials
Stonewall Treatment Evaluation Project
Evaluation of a Harm Reduction Treatment for Methamphetamine-Using Men Who Have Sex With Men (MSM)
Status: Enrolling
Updated:  10/8/2012
University of California, San Francisco
mi
from
San Francisco, CA
Stonewall Treatment Evaluation Project
Evaluation of a Harm Reduction Treatment for Methamphetamine-Using Men Who Have Sex With Men (MSM)
Status: Enrolling
Updated: 10/8/2012
University of California, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Stonewall Treatment Evaluation Project
Evaluation of a Harm Reduction Treatment for Methamphetamine-Using Men Who Have Sex With Men (MSM)
Status: Enrolling
Updated:  10/8/2012
San Francisco AIDS Foundation
mi
from
San Francisco, CA
Stonewall Treatment Evaluation Project
Evaluation of a Harm Reduction Treatment for Methamphetamine-Using Men Who Have Sex With Men (MSM)
Status: Enrolling
Updated: 10/8/2012
San Francisco AIDS Foundation
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study Targeting Affect Regulation
A Pilot RCT of Expressive Writing With HIV-Positive Methamphetamine Users
Status: Enrolling
Updated:  10/8/2012
UCSF Center for AIDS Prevention Studies
mi
from
San Francisco, CA
Study Targeting Affect Regulation
A Pilot RCT of Expressive Writing With HIV-Positive Methamphetamine Users
Status: Enrolling
Updated: 10/8/2012
UCSF Center for AIDS Prevention Studies
mi
from
San Francisco, CA
Click here to add this to my saved trials